Advanced psoriasis treatment: Development and optimization of resorcinol-loaded nanoemulgel with lavender oil

Abstract

<p>Psoriasis, a long-term autoimmune illness, affects 2%–5% of people worldwide. Drugs from BCS class II that are commonly used to treat psoriasis include resorcinol, which presents burning feelings and itchiness as adverse effects. To minimize adverse effects and increase the effectiveness of treatment, a topical nanoemulgel was developed in the current research. A resorcinol-loaded nanoemulgel was developed using the nanoemulsion technique, and the Design Expert<sup>®</sup> CCD method was used for optimization. Particle size (PS), zeta potential (ZP), and percentage of entrapment efficiency (EE%) served as the foundation for the optimization. The morphology, chemical interactions between excipients, crystallinity, and thermal behavior of the optimized resorcinol-loaded nanoemulgel were examined by TEM, FTIR, and XRD physicochemical studies. The resorcinol-loaded nanoemulgel was successfully loaded and characterized. For the in vitro release, the dialysis bag technique was employed. The ideal PS, PDI, and ZP values for the optimized resorcinol-loaded nanoemulgel were 31.32 ± 3.1 nm, 0.24 ± 0.005, and −10.6 ± 1.0 mV, respectively. The FTIR data revealed that no chemical interactions were observed between the components of resorcinol-loaded nanoemulgel, while the TEM results supported the spherical shape. The in vitro study confirmed a sustained release of resorcinol-loaded nanoemulgel.</p>